Gender Matter in Isotretinoin Therapy for Acne Vulgaris? A Retrospective StudyNevena Skroza, Riccardo Pampena#, Ersilia Tolino*#, Sara Zuber, Giorgio La Viola, Nicoletta Bernardini, Ilaria Proietti, Veronica Balduzzi, Fowzieh Rasras, Concetta Potenza
Dermatology Unit “Daniele Innocenzi”, Dept. of Medical and Surgical Sciences and Biotechnologies, Sapienza University of Rome, Polo Pontino, Terracina, Italy
- *Corresponding Author:
- Ersilia Tolino
Dermatology Unit “Daniele Innocenzi”
“Sapienza” University of Rome, A. Fiorini Hospital
via Firenze, snc 04019, Terracina (LT),Italy
Tel: +39 0773708811
E-mail: [email protected]
Received date: April 20, 2015; Accepted date: August 26, 2015; Published date: August 31, 2015
Citation: Skroza N, Pampena R, Tolino E, Zuber S, La Viola G, et al. (2015) Gender Matter in Isotretinoin Therapy for Acne Vulgaris? A Retrospective Study. J Clin Exp Dermatol Res 6:300. doi: 10.4172/2155-9554.10000300
Copyright: © 2015 Skroza N, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Introduction: Gender differences have been recently highlighted for several aspects of acne vulgaris such as epidemiology, pathogenesis, clinical course, quality of life and treatment outcome. In particular a shorter but more severe clinical course has been reported in males than in females; nevertheless, usually men have their quality of life less affected.
Aim: To determine if the response and the adverse events to 1 cycle of oral isotretinoin therapy can be influenced by gender.
Methods: A retrospective study was conducted on consecutive patients affected by acne vulgaris and treated with oral isotretinoin. Global acne grading system (GAGS), acne-related quality of life (AQoL) and isotretinoin-related adverse events were considered as outcome measures and were evaluated before (T0), every month during administration and 4 weeks after the withdrawal (T1) of oral isotretinoin therapy. Mann-Whitney U test and Wilcoxon signed-rank test were used for quantitative parameters and Fisher exact test for qualitative ones.
Results: Forty-nine acneic patients were retrospectively selected (33 males 67.3% and 16 females -32.7%; median age: 19 years). Patients had received a median dosage of isotretinoin of 0.4 mg/kg/die for a median period of 5 months; no differences in outcome measures among genders were reported.
Limitations: The study is retrospective and the sample is small and not homogenously distributed among genders, as males are double in number than females.
Conclusions: In our study population gender didn't influence neither the clinical and the quality of life outcome measures nor the occurrence of adverse events to oral isotretinoin therapy for acne.